South Korea · Delayed Price · Currency is KRW Angiolab Company Description
Angiolab, Inc., a biotechnology company, develops medicine with angiogenesis inhibitors for treating angiogenesis-related diseases.
Its Phase I products consist of AL101-PSO for psoriasis. The company’s Phase II a clinical trial products include AL101- NASH for the treatment of non-alcoholic steatohepatitis; AL101-OME, for otitis media with effusion; and AL102-PDT for periodontitis.
Its Phase II clinical trial products comprise AL101-AMD to treat age related muscular degeneration; and AL101-AOB for the treatment of abnormal obesity.
In addition, the company provides ob-X for visceral fat reduction; and specific function and health functional food.
Further, it offers AL201-AB, which is in the pre-clinical stage for the treatment of cancer, ocular diseases, etc. The company was founded in 1999 and is headquartered in Daejeon, South Korea.
| Country | South Korea |
| Founded | 1999 |
| Industry | Biological Products, Except Diagnostic Substances |
| CEO | Min-Young Kim |
Contact Details
Address: Hanshin S Mecca Suite 159 Daejeon South Korea | |
| Phone | 82 4 2867 5785 |
| Website | angiolab.co.kr |
Stock Details
| Ticker Symbol | 251280 |
| Exchange | Korea New Exchange |
| Reporting Currency | KRW |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Min-Young Kim | Chief Executive Officer |